The Treatment of Breakthrough Pain (BTP) in People with Complex Regional Pain Syndrome (CRPS)
Method
From April 15, 2008 to April 22, 2008, a survey was conducted by the RSDSA regarding the treatment of BTP in people with CRPS, and specifically, the use of Fentora® in this population. The survey was sent via e-mail to 3,978 contacts from the Electronic Alert listserv of the RSDSA. Of these 3,978 invitations, there were 574 completed survey responses (14.4%). The survey consisted of 10 questions surrounding the topics of BTP and the use of narcotics for BTP, with 2 specifically regarding Fentora® (See ‘Question-Answer Details’ for the survey questions).
Results
Of the 574 responses of people with CRPS, 94.5% experience BTP, defined as moderate to severe flares of pain that occur when persistent or baseline pain is pretty well managed. During a BTP episode, the average pain rating score is 8.2/10, with 10 being the Worst Pain Possible, with 28.7% of respondents at 10. Of the 66.5% of respondents currently taking opioids for their pain, 52.4% take a short-acting opioid to manage their BTP.
Of the 52.4% of respondents that take a short-acting opioid to manage BTP, only 4.7% have been prescribed Fentora® for BTP, and for 85% of these respondents, insurance companies denied payment for Fentora® because they did not have a cancer diagnosis.
Question-Answer Details
There were 181 comments associated with this question. For the complete list of comments, with contact information, see Appendix I.
There were 209 comments associated with this question. For a complete list of comments, with contact information, see Appendix II.
There were 713 ‘Other’ responses for this question. For a complete list of responses, with contact information, see Appendix III.
Added April 23, 2008 |
